ASP Isotopes Inc. — Form 10-Q Summary
Business context and reporting period
ASP Isotopes Inc. is a pre-commercial advanced materials company developing Aerodynamic Separation Process technology to enrich isotopes, initially targeting Carbon-14, Molybdenum-100, Silicon-28 and Uranium-235. Operations are primarily conducted through subsidiaries in South Africa, Guernsey and the United Kingdom. The first commercial-scale enrichment plant is under construction in South Africa.
This unaudited quarterly report covers the three months ended March 31, 2023, with comparative results for the three months ended March 31, 2022. The company has not generated revenue from isotope sales and has no products approved for commercial sale.
Financial condition and key metrics
| Metric | Three months ended March 31, 2023 | Three months ended March 31, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $207,334 | $293,051 |
| General and administrative expense | $3,517,490 | $565,202 |
| Total operating expenses | $3,724,824 | $858,253 |
| Loss from operations | $(3,724,824) | $(858,253) |
| Net loss | $(3,615,078) | $(857,588) |
| Net loss per share, basic and diluted | $(0.12) | $(0.03) |
| Cash used in operating activities | $(1,444,965) | $(287,947) |
| Cash used in investing activities | $(362,056) | $(898,918) |
| Cash provided by financing activities | $4,493,610 | $2,232,964 |
| Cash at period end | $5,082,290 | $3,770,579 |
Gross margin, operating margin and net margin are not meaningful because the company had no revenue. The March 31, 2023 balance sheet included total assets of $14.6 million, total liabilities of $2.7 million and stockholders’ equity of $11.9 million.
Property and equipment of $8.0 million consisted entirely of construction in progress for the South African plant. No depreciation was recorded because the plant was not complete or in service.
Debt was limited to $33,854 of non-interest-bearing promissory notes, which automatically extended monthly. The company reported no bank debt. Operating lease liabilities totaled $744,501, including $46,551 current and $697,950 noncurrent.
Material changes versus the prior comparable period
- Net loss increased to $3.6 million from $0.9 million, primarily due to higher general and administrative expense.
- General and administrative expense increased by approximately $3.0 million, including $2.1 million of stock-based compensation compared with $20,803 in the prior-year period.
- Research and development expense decreased by approximately $85,717, or about 29%.
- Operating cash use increased to $1.4 million from $0.3 million.
- In March 2023, the company issued 3,164,557 common shares and warrants to purchase 3,164,557 additional shares for gross proceeds of $5.0 million. Net proceeds were approximately $4.5 million after issuance costs.
- Shares outstanding increased to 37,385,684 at March 31, 2023 from 35,907,127 at December 31, 2022. The March financing also created potential dilution from common warrants and placement-agent warrants.
- Stockholders’ equity increased to $11.9 million from $9.8 million despite the quarterly loss, primarily because of the March equity financing and $2.1 million of stock-based compensation.
- Foreign currency translation produced a $1.0 million other comprehensive loss in the quarter, compared with a $229,257 loss in the prior-year period.
Guidance, outlook, commentary and unusual items
- Management expects significant additional funding will be required to complete the first enrichment facility and begin operations. The filing states that cash of $5.1 million at March 31, 2023 is not expected to fund operating and capital requirements for more than 12 months from issuance of the financial statements, raising substantial doubt about going-concern status.
- A separate risk-factor discussion states that existing cash and recent financing proceeds are expected to fund operations for at least the next 12 months. Investors should reconcile this apparent inconsistency with the formal liquidity and going-concern disclosure.
- The initial phase of the Klydon turnkey contract is intended to support production of at least 5 kilograms of Mo-100 and has a stated cost of $6.8 million. A second phase would increase capacity to 20 kilograms at an additional stated cost of $6.0 million. Approximately $7.2 million had been paid under the contract and capitalized as construction in progress.
- Klydon failed to complete contractual obligations by December 31, 2022. The company perfected its security interest in certain Klydon assets on April 4, 2023 and acquired certain intellectual property. The company expects to account for the transaction as an asset acquisition in the second quarter; no recovery receivable was recorded as of March 31, 2023.
- The company has not produced experimental samples of finished isotopes, demonstrated commercial-scale production, obtained applicable approvals for its planned products or established sales and marketing capabilities. Management does not expect substantial isotope availability until at least 2024, and commercial U-235 production, if permitted, would be several years away or may never occur.
- The company identified a material weakness in internal control over financial reporting and concluded that disclosure controls and procedures were not effective as of March 31, 2023. The planned remediation includes hiring accounting, finance and information-technology personnel or consultants with public-company experience.
- The company received an October 2022 letter asserting that its Klydon technology license conflicts with a pre-existing sublicense involving Radfarma. Management believes the claims lack merit, but an adverse outcome could impair the company’s core technology rights.
- On May 5, 2023, Nasdaq notified the company that its closing bid price had been below $1.00 for 30 consecutive business days. The company was given until November 1, 2023 to regain compliance, subject to Nasdaq rules.
Principal risks and contingencies
- Substantial doubt regarding the company’s ability to continue as a going concern and dependence on additional equity, debt or collaborative financing.
- Execution risk in completing, commissioning and operating the South African enrichment plant, including contractor performance, construction costs, supply-chain interruptions, power availability and technical feasibility.
- Regulatory and export-control risks associated with isotope enrichment, medical applications, nuclear materials and potentially dual-use technology.
- Technology and commercialization risk: the company has no approved products, no sales, no demonstrated commercial production and limited operating history.
- Dependence on Klydon, third-party suppliers and a limited number of potential future customers.
- Intellectual-property risk, including lack of patent registrations and the asserted conflict with the Radfarma sublicense.
- Potential dilution from outstanding options, warrants, restricted shares and future capital raises.
- Foreign-exchange, political, infrastructure, cybersecurity, hazardous-material and South African operating risks.
Most important facts for investors to verify
- Whether the company can raise sufficient capital before its cash is depleted and how management resolves the inconsistent 12-month liquidity statements.
- Current progress, remaining cost, revised schedule and commercial readiness of the South African Mo-100 plant following Klydon’s missed obligations.
- The valuation, legal status and strategic effect of the intellectual property acquired from Klydon on April 4, 2023.
- Whether the company has regained Nasdaq’s minimum bid-price compliance and the potential effect of any reverse split or other remedial action.
- The status and potential impact of the NMS/Radfarma license dispute and the company’s broader intellectual-property protection.
- Actual technical evidence supporting production of Mo-100, C-14, Si-28 or U-235, including any samples, test results, permits or customer commitments.
- The magnitude of future dilution from 3.4 million warrant shares, outstanding options, restricted stock and additional financing needs.
- Progress in remediating the material weakness in internal controls and strengthening the finance and accounting organization.